Neoadjuvant chemo reduces bladder Ca mortality

Orlando, FL-After 7 years follow-up, researchers from the UnitedKingdom report that a landmark clinical trial in bladder cancer now showsa significant reduction in mortality if patients underwent 3 months of neoadjuvantchemotherapy prior to definitive surgery or radiation for muscle-invasivebladder cancer.

Related Videos

Oral testosterone undecanoate shows promising results for first use in the real world

Related Content

Advertisement

August 4th 2025

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

August 4th 2025

Nedosiran explored in primary hyperoxaluria type 3

Jason M. Broderick

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

August 4th 2025

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Jason M. Broderick

FDA new drug application filing expected by the end of 2021.

August 4th 2025

FDA approves androgen inhibitor for metastatic PCa

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

August 4th 2025

Blood test could guide treatment for kidney cancer

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

August 4th 2025

BCG for bladder cancer in short supply

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.

Related Content

Drug Therapy

Drug Therapy

Advertisement

August 4th 2025

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

August 4th 2025

Nedosiran explored in primary hyperoxaluria type 3

Jason M. Broderick

The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.

August 4th 2025

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Jason M. Broderick

FDA new drug application filing expected by the end of 2021.

August 4th 2025

FDA approves androgen inhibitor for metastatic PCa

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).

August 4th 2025

Blood test could guide treatment for kidney cancer

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.

August 4th 2025

BCG for bladder cancer in short supply

Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-Guérin is currently unavailable from one manufacturer.